Search

Displaying results 3671 - 3680 of 4692 in total
  1. Drug

    Glucose-6-Phosphate

    go.drugbank.com/drugs/DB03581
    Experimental

    An ester of glucose with phosphoric acid, made in the course of glucose metabolism by mammalian and other cells.

  2. Drug

    D-Asparagine

    go.drugbank.com/drugs/DB03943
    Experimental

    It is biosynthesized from ASPARTIC ACID and AMMONIA by asparagine synthetase. (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed)

  3. Drug

    IDM-1

    go.drugbank.com/drugs/DB05292
    Experimental

    It is comprised of MAK(Monocytes-derived Activated Killer) cells associated with MDX-210, a bispecific anti-HER-2/neu antibody developed by Medarex Inc.

  4. Drug

    AME-527

    go.drugbank.com/drugs/DB05879
    Experimental

    AME-527 was generated by protein engineering and identified from a library of antibody variants based on its improved binding properties.

  5. Drug

    (S)-Warfarin

    go.drugbank.com/drugs/DB14055
    Investigational

    Warfarin consists of a racemic mixture of two active enantiomers—R- and S- forms—each of which is cleared by different pathways.

    Categories: Vitamin K Antagonists
  6. Drug

    Autologous Non-Hematopoietic Peripheral Blood Stem Cells

    go.drugbank.com/drugs/DB15867
    Investigational

    Autologous non-hematopoietic peripheral blood stem cells have been created into a formulation for use in a clinical trial (NCT04473170) by the Abu Dhabi Stem Cells Center.

  7. Drug

    Jaktinib

    go.drugbank.com/drugs/DB17545
    Investigational

    Jaktinib is a JAK 1, JAK 2 and JAK 3 inhibitor, being developed by Suzhou Zelgen Biopharmaceuticals.

  8. Drug

    Asundexian

    go.drugbank.com/drugs/DB19088
    Investigational

    Asundexian is under investigation in clinical trial NCT05686070 (A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk

  9. Drug

    EP-2104R

    go.drugbank.com/drugs/DB05675
    Experimental

    It is being developed by EPIX Pharmaceuticals, Inc.

  10. Drug

    Edodekin alfa

    go.drugbank.com/drugs/DB15631
    Investigational

    investigation in clinical trial NCT01468896 (Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That Is Recurrent, Metastatic, or Cannot Be Removed by